MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, VTYX had -$331K decrease in cash & cash equivalents over the period. -$17,558K in free cash flow.

Cash Flow Overview

Change in Cash
-$331K
Free Cash flow
-$17,558K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Total operating expenses
84,304 -
Loss from operations
-84,304 -
Interest income
7,088 -
Other expense
-40 -
Total other (income) expense
7,048 -
Net loss
-22,829 -54,427
Depreciation
58 161
Amortization of right-of-use assets - operating
268 518
Stock-based compensation
4,601 9,606
Accretion of marketable securities, net
-1,063 -2,907
Prepaid expenses and other assets
-1,943 -1,988
Operating lease liabilities
-270 -500
Accounts payable
101 -2,236
Accrued expenses
-317 802
Net cash used in operating activities
-17,508 -46,995
Purchases of marketable securities, available-for-sale
34,774 53,348
Proceeds from maturities of marketable securities, available-for-sale
51,875 105,013
Purchases of property and equipment
50 58
Net cash provided by (used in) investing activities
17,051 51,607
Proceeds from exercise of stock options
203 -
Proceeds from issuance of common stock under employee stock purchase plan
0 68
Net cash provided by financing activities
203 68
Effect of exchange rates on cash, cash equivalents and restricted cash
-77 361
Net increase in cash, cash equivalents and restricted cash
-331 5,041
Cash and cash equivalents at beginning of period
28,235 -
Cash and cash equivalents at end of period
32,945 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Ventyx Biosciences, Inc. (VTYX)

Ventyx Biosciences, Inc. (VTYX)